SLC49A3 and ovarian cancer: Similarly, MFSD7 rs6840253 was associated with a reduction of ovarian cancer risk (invasive OR 0.81, 95% CI 0.66–1.0, p = 0.05; serous invasive OR 0.76, 95% CI 0.58–0.98, p = 0.03), as was ZNF200 rs186493 (invasive OR 0.83, 95% 0.71–0.82, p = 0.02; invasive serous OR 0.82, 95% CI 0.68–0.98, p = 0.03).